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Abstract
Background and purpose: Flattening filter free (FFF) beams with high dose rate are increasingly used for
stereotactic body radiotherapy (SBRT), because they substantially shorten beam-on time. The physical properties of
these beams together with potentially unknown radiobiological effects might affect patient safety. Therefore here
we analyzed the clinical outcome of our patients.
Material and methods: Between 3/2010 and 2/2014 84 patients with 100 lesions (lung 75, liver 10, adrenal 6,
lymph nodes 5, others 4) were treated with SBRT using 6 MV FFF or 10 MV FFF beams at our institution. Clinical
efficacy endpoints and toxicity were assessed by Kaplan-Meier analysis and CTCAE criteria version 4.0.
Results: Median follow-up was 11 months (range: 3–41). No severe acute toxicity was observed. There has been
one case of severe late toxicity (1%), a grade 3 bile duct stricture that was possibly related to SBRT. For all patients,
the 1-year local control rate, progression free survival and overall survival were 94%, 38% and 80% respectively, and
for patients with lung lesions 94%, 48% and 83%, respectively.
Conclusions: No unexpected toxicity occurred. Toxicity and treatment efficacy are perfectly in range with studies
investigating SBRT with flattened beams. The use of FFF beams at maximum dose rate for SBRT is time efficient and
appears to be safe.
Keywords: Flattening filter free, Stereotactic body radiotherapy (SBRT), Stereotactic ablative radiotherapy (SABR),
Dose rate, Toxicity
Background
Novel linear accelerator technology allows compensating
non uniform photon fluence by use of intensity modulation
instead of directing the beam through a flattening filter. A
major advantage of using flattening filter free (FFF) beams
is that the dose rate can be multiplied in comparison to flat-
tened beams thereby shortening beam-on time [1,2]. This is
especially attractive when a high dose per fraction is used,
e.g. in the case of stereotactic body radiotherapy (SBRT).
Although FFF beams at maximum dose rate have been
rapidly introduced into clinical use, little clinical data
about their safety and efficacy are available.
Shortening of treatment time improves patient comfort
especially in elderly and frail patients and was shown to
improve patient stability [2-4]. On the other hand, it may
introduce novel hazards, e.g. in case of patient or organ
movement there is less time to intervene. There are also
dosimetric uncertainties due to the interplay effect; e.g.
Ong et al. [5] investigated the dosimetric impact of intra-
fractional motion during spine radiosurgery and found an
increased sensitivity of the target coverage and dose to the
spinal cord if FFF beams are used compared to flattened
beams.
Because of putative unknown radiobiological hazards
of using high instantaneous dose rate, several research
groups recently performed preclinical investigations.
Using exclusively in vitro assays, four studies could not
detect any effect of high dose rate on clonogenic cell
survival [6-9], whereas Lohse et al. [10] found that FFF
beams given with high dose per pulse impaired clono-
genic survival and this effect became significant with
high dose per fraction. Only one preclinical study so
far investigated the effect of extremely high dose rate
in vivo. Using a murine lung fibrogenesis model as well as
human xenografts and murine syngenic and orthotopic
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lung tumors a differential response between normal and
tumor tissue in mice was shown when ultrahigh-dose-rate
flash irradiation was compared to conventional dose
rate irradiation [11]. Also classical radiobiological con-
siderations seem to support a dose rate effect of very
high dose rates. Based on the linear quadratic model, in
a recent comprehensive review it was suggested that the
influence of high dose rate on tumor response and toxicity
is determined by beam-on time with late reacting tissue
being more sensitive to dose rate effect than tumors and
early reacting tissues [12].
Our clinic was the first to use FFF linear accelerator
technology at maximum dose rate for SBRT in patients.
With the lack of a clear biological rationale not to use
FFF beams we introduced this technology assuming that
the benefit in terms of increased treatment efficiency
would outweigh the minimal risk of additional toxicity.
Here we report the results of our patients with focus on
patient safety, which is the biggest patient cohort re-
ported so far.
Methods
From March 2010 to February 2014 84 patients were
treated with SBRT using FFF beams at our institu-
tion. Patient and treatment parameters are listed in
Table 1. Clinical data were collected retrospectively
from the patient charts and radiotherapy parameters
were extracted from the Eclipse treatment planning
system.
Patients and lesions treated
Altogether 84 consecutive patients with 100 lesions
were included in this study. Inclusion criteria were
defined as the use of FFF beams at maximum dose rate
for SBRT. Patients with pancreatic lesions were ex-
cluded due to the pre- or postoperative setting of
radiotherapy. Of the 84 patients, 48 were male and 36
female. Patient age ranged from 19 to 88 years (median:
67 years).
The irradiated lesions were localized in the lung 75
(75%), liver 10 (10%), adrenal glands 6 (6%), lymph node
5 (5%) or other sites 4 (4%) (Table 1). Of all tumors 25%
were primary tumors (19 non-small cell lung cancers
and 2 small cell lung cancers with histology, 2 solitary
lung nodules suspicious for primary lung cancer but
without histology, 2 liver cancers), 45% metastases, 16%
tumor recurrences and for 14% no differentiation was
possible. Mean gross tumor volume (GTV) was 15.4
cm3 (range: 0.6–126.7 cm3). BED was ≥100 Gy in 33% of
the patients. For patients with lung lesions the mean
forced expiratory volume (FEV1) was 1.87 l (range:
0.41–4.30 l) and the mean diffusion capacity (DLCO)
was 66% (24–115%).
Table 1 Patient and treatment parameters
N1
Gender
Male 48 (57%)
Female 36 (43%)
Age
Mean/Median [years] 66/67
Range [years] 19 - 88
RT localization
Lung 75 (75%)
Liver 10 (10%)
Adrenal gland 6 (6%)
Lymph node 5 (5%)
Other site 4 (4%)
Lesions treated
Primary tumor 25 (25%)
Metastasis 45 (45%)
Tumor recurrence 16 (16%)
Primary tumor/Metastasis 14 (14%)
Prescription dose
48 Gy/4 fx 19 (19%)
40 Gy/4 fx 10 (10%)
35 Gy/5 fx 6 (6%)
60 Gy/10 fx 5 (5%)
50 Gy/10 fx 5 (5%)
Other 55 (55%)
BED
<100 Gy 66 (66%)
≥100 Gy 34 (34%)
GTV size
Mean [cm3]/Median [cm3] 15.4/6.7
Range [cm3] 0.60 - 126.7
<14 cm3 65 (65%)
≥14 cm3 35 (35%)
PTV size
Mean [cm3]/Median [cm3] 58.2/35.2
Range [cm3] 5.9 - 368.7
Energy
6 MV 84 (84%)
10 MV 16 (16%)
Dose rate
Mean [MU/min.]/Median [MU/min.] 1319/1400
Range [MU/min] 451 - 2400
N1 = number of patients or lesions if not indicated otherwise. (RT: Radiation
Therapy, fx: fractions, BED: Biologically Effective Dose, GTV: Gross Tumor
Volume, PTV: Planning Target Volume, MU: Monitor Unit).
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Treatment
A TrueBeam linear accelerator (Varian Medical Systems,
Palo Alto, CA) was used to apply 6 MV FFF or 10 MV
FFF beams with a maximum dose rate of 2400 MU/min.
Overall mean dose rate considering all treatments was
1319 MU/min (range: 451–2400 MU/min). Patients
were treated using Volumetric Modulated Arc Therapy
(VMAT) with 1–4 arcs. The tumors were delineated as
internal target volumes (ITV) on 4-dimensional computed
tomographies (4DCTs). For peripheral and central lung
lesions the planning target volume (PTV) was defined
as the ITV + 6 mm and 3 mm, respectively, and for liver,
adrenal gland and lymph node lesions ITV to PTV mar-
gins of 5 – 10 mm were used. Prescribed doses were
21–66 Gy in 3–15 fractions. In case of curative intention a
BED of at least 100 Gy was envisaged (usually 48 Gy in 3
to 4 fractions, 10 × 6 Gy for tumors adjacent to the thor-
acic wall, 8 × 7.5 Gy for centrally located lung tumors).
For palliative indications individualized and risk-adapted
regimens were used depending on tumor localization,
remaining organ function and anticipated life expectancy.
Normal tissue constraints for lung tumors were adopted
from current RTOG protocols (RTOG 0618 and 0915,
http://www.rtog.org). Treatment planning was performed
on the average projection of the 4DCT in the Eclipse
treatment planning system (Varian Medical system, Palo
Alto). The dose was prescribed inhomogeneously to the
PTV in a way that 95% of the PTV should receive 100% of
the prescribed dose with maximum doses between 125%
to 152% [13].
Follow up
The patients were usually seen at three months after SBRT
and then in 6-monthly intervals. For follow-up imaging
either CT of the chest or FDG PET/CT were used.
Data analysis
Local control rate (LCR), progression free survival (PFS)
and overall survival (OS) were assessed at 1 year after
start of treatment. Local tumor recurrence or distant
relapse were evaluated following the RECIST criteria
version 1.1 [14]. In case RECIST criteria were not useful,
an FDG PET/CT was performed to differentiate between
tumor recurrence and lung fibrosis. Acute and late toxic-
ities were assessed according to the Common Termin-
ology Criteria for Adverse Events Version 4.0 (CTCAE
v4.0). Acute toxicity was defined as adverse event within a
90 days period from start of treatment and late toxicity as
adverse event thereafter. Grade 3–4 toxicity was assessed
for all patients and grade 1–2 toxicity only for radiological
changes in the lung (pneumonitis, pleural effusion, atelec-
tasis) due to the retrospective character of the analysis.
The biologically effective dose (BED) was calculated by
the following formula: BED ¼ nd 1þ dα=β
 
, whereby α/β
was assumed to be 10 (n: number of fractions, d: dose per
fraction). BED was calculated and analyzed for prescribed
dose.
Statistics
Descriptive statistics were used to calculate number,
percentage, mean, median and standard deviation. Sur-
vival curves were calculated by Kaplan Meier analysis.
Log-rank test and Cox regression were used to analyze
correlation of outcome with BED, tumor size and mean
dose rate. For log-rank test a BED of 100 Gy and a
tumor volume of 14 cm3 (diameter ~ 3 cm) were chosen
as cut-off values because BED above 100 Gy and tumor
size ≤ 3 cm were associated with improved tumor control
rates after SBRT with flattened beams [15-20]. A p-value
of ≤ 0.05 was considered to be statistically significant.
All statistical analyses described above were performed
using the software program SPSS Version 22 (IBM SPSS
Statistic Software).
Results
Toxicity
There was no treatment related mortality or ≥ grade 3
acute toxicity observed. Only 2 patients (3%) presented
with grade 2 acute pneumonitis (Table 2).
Late toxicity could be assessed in 74 of 84 patients,
who had a minimum follow-up of 90 days from start of
treatment. One patient with centrally located liver metas-
tasis developed a grade 3 bile duct stenosis after SBRT
with 4 × 12 Gy. However this patient also had hemihepa-
tectomy after SBRT with the resection line being close to
the bile duct and the relationship to both treatments re-
mains unclear. The patient received a percutaneous biliary
drainage and was still alive at last follow-up, 22 months
after treatment. Of 75 lung lesions 63 were peripherally
and 12 centrally located. No ≥ grade 3 late lung toxicity
Table 2 Acute and late lung toxicity in 75 patients with
lung lesions
Adverse event Grade
I II ≥III
Acute toxicity
Pneumonitis 11% 8% -
Pleural Effusion 3% - -
Atelectasis 8% - -
Late toxicity
Pneumonitis 44% 6% -
Pleural Effusion 14% 2% -
Atelectasis 20% 2% -
If patients were treated at multiple sites, each site was analyzed separately.
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occurred and there have been only 4 patients (5%) with
grade 2 late lung toxicity: two cases with pneumonitis, one
case with pneumonitits and atelectasis and one case with
pleural effusion.
Treatment efficacy
The median follow-up of all patients was 11 ± 10 months.
For all patients the 1-year LCR, PFS and OS were 94%,
38% and 80% and for patients with lung lesions 94%, 48%
and 83%, respectively (Figure 1). If lung lesions are strati-
fied into primary lung cancers (n = 48) and lung metasta-
ses of other histologies (n = 27) the 1-year LCR, PFS and
OS were 93%, 60% and 85% for primary lung cancers and
95%, 29% and 77% for lung metastases. All patients with
liver metastases (n = 9) or thoracic lymph nodes (n = 4)
remained locally stable after one year and all but one pa-
tient with adrenal lesion (n = 5). No significant correlation
could be found between GTV size and LCR, if all lesions
were analyzed, whereas for lung lesions there was a signifi-
cant negative correlation when using the log-rank test
with a cut-off value of 14 cm3 (p = 0.02), but not if Cox
regression analysis was performed (Table 3). No significant
correlation was found for LCR and the PTV surrounding
BED (p = 0.52), but all patients irradiated with BED ≥ 100
Gy remained locally stable after 1 year of treatment, or
between LCR and mean dose rate (p = 0.44).
Discussion
In the present study we analyzed the clinical results of
the patients treated with SBRT and FFF beams at max-
imum dose rate at our institution. We included all pa-
tients treated so far, although it is a hetergenous cohort,
because we wanted to analyze overall patient safety and
detect any unexpected toxicity rather than investigating
specific tumor sites. We show in 84 patients with 100 le-
sions in the lung, liver, adrenal glands, lymph nodes and
other sites that the use of FFF beams for these indications
is associated with low rates of acute and early late toxicity
and results in excellent early local tumor control. The re-
sults shown appear similar to results of studies using
SBRT with flattened beams and lower dose rates.
Most of the data published about FFF beams explored
their physical properties [1,2,13,21-25]. Altogether these
studies show that the use of FFF beams significantly re-
duces treatment time for high single fractions and dose
distributions are comparable to flattened beams. Apart
from the technical benefits there have been some concerns
about patient safety when FFF beams with high instantan-
eous dose rate are used due to physical uncertainties of
beam application and biological considerations.
A physical concern is that very short beam-on times
introduce dosimetric uncertainties in case of tumor shifts.
In patients with spinal metastases Ong et al. [5] investi-
gated shifts of 1–5 mm during 5–30 seconds in the case
of single fraction SBRT with flattened or FFF beams. Dosi-
metric deviations in FFF plans were approximately 2-fold
greater than with flattened beams, which resulted in sig-
nificant overdosage of the spinal cord and underdosage of
the GTV with increasing shift size and dependent on shift
duration. In their study GTV to PTV margins of 2–3 mm
were used. In our clinic until recently we did not use
SBRT for spinal metastases and therefore the lesions
analyzed had usually less proximity to critical organs.
In addition we fractionated SBRT und applied much
larger margins (3–10 mm). Therefore potential dosimetric
uncertainties are much less important for the treatments
reported by us.
Recently several preclinical studies were published in-
vestigating the biology of high instantaneous dose rate
in clonogenic cell survival assays [6-10]. Sorensen et al.
used Chinese hamster and FADU cells irradiated with 6
MV flattened beams with single doses up to 10 Gy, dose
Figure 1 Kaplan Meier curves for local control rate (LCR), overall survival (OS) and progression free survival (PFS) for all lesions
(left side) and separately for lung lesions (right side).
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rates between 5 and 30 Gy/min and instantaneous dose
rates per pulse between 56 and 338 Gy/s [8]. They did
not find any effect of high instantaneous dose rates on
cell survival. In contrast, Lohse et al. [10] irradiated dif-
ferent glioblastoma cell lines using 10 FFF beams with
overall dose rates of 0.2 Gy/min or 24 Gy/min and in-
stantaneous dose rates per pulse up to 350 Gy/s and
found that high dose per pulse but not delivery time
reduced clonogenic survival. The anti-tumor cell effect
of high dose rate increased with fraction size and be-
came significant at 10 Gy. Three additional preclinical
studies were published investigating FFF beams in differ-
ent cell-lines, all showing no difference in clonogenic cell
survival if FFF beams with dose rates up to 24 Gy/min are
used [6,7,9]. A preclinical study using clinically more rele-
vant in vivo models was recently published by Favaudon
et al. [11]. The authors used a lung fibrogenesis model
and human tumor xenografts as well as syngenic and
orthotopic murine lung tumors and treated them with
high single fractions of ultrahigh-dose-rate flash irradi-
ation (dose rate ≥ 40 Gy/s) versus conventional dose rate
irradiation (≤0.03 Gy/s). Interestingly both techniques
exerted similar anti-tumor effects but the ultrahigh-dose-
rate flash irradiation induced much less TGF-β dependent
lung fibrosis indicating a differential response between
normal and tumor tissue. A somehow contrary differential
effect was recently suggested and modeled by Ling and
coauthors considering various factors such as different
mechanisms of DNA repair and implications of the α/β
model [12]. Their conclusion was that the dose rate effect
is not determined by the instantaneous dose rate but in-
stead by beam-on time, which mostly affects late reacting
tissues. By computing with the LQ Model they calculated
for example that, if a single fraction of 10 Gy is given in 2
minutes instead of 10 minutes, this acceleration increases
BED to the tumor (α/β = 10) by ~1.5% and BED to late
responding tissue (α/β = 3) by ~3.9%.
We previously demonstrated that the gain in beam-on
time by using 6 or 10 FFF beams in comparison to a 6
MV flattened beam increases with dose per fraction and
amounts to several minutes when fractions beyond 10
Gy are used [2]. Therefore based on the paper by Ling
et al. there might be clinical situations, e.g. in case of
spinal SBRT when high doses are given in close proxim-
ity to critical serial organs, when the use of FFF beams
with maximum dose rate might lead to a small increase
of complications.
Only few clinical studies so far investigated the clinical
outcome of SBRT with FFF beams in patients [26-31]
(Table 4). Almost all studies except the studies by
Prendergast and Wang were conducted from the re-
search group of the Humanitas Cancer Center in Milano
[26-28,30,31]. Generally, patient numbers in these studies
were small and the follow-up was short. In the biggest
retrospective patient series, 67 patients with 70 lesions in
different organs were treated with SBRT using FFF beams
[30]. The treatment schedules ranged from 32–48 Gy in 4
fractions for lung and 75 Gy in 3 fractions for liver tu-
mors. With a minimum follow-up of 3 months two acute
grade 3 lung toxicities (3%) were observed and 89% of pa-
tients showed a tumor response at 60–90 days after SBRT.
In the only prospective study published with FFF beams
so far, 40 prostate cancer patients were treated with 35 Gy
in 5 fractions [26]. After a median follow-up of 11 months
no grade 3 toxicity was observed.
In the studies of the Milano group the dose was pre-
scribed homogeneously to the 95% isodose [26-28,30]. In
contrast, we use a SBRT protocol, where the dose is pre-
scribed inhomogeneously to the PTV with dose maxima in
the tumor of up to 152%. Therefore, in case of similar dose
prescription, the patients reported by us received a substan-
tially higher dose to the GTV and immediately surrounding
PTV without evidence of increased toxicity. The only study
that reported substantial high-grade toxicity when using
SBRT with FFF beams was published by Prendergast et al.
[29]. This study included 64 patients with lung malignan-
cies receiving 30–60 Gy in 3–5 fractions. Median follow
up was 11.5 months and 6 cases of severe ≥ grade 3 late
toxicity (12%) occurred; of these, five were pulmonary and
one nerve-related. One patient died because of sepsis after
pneumonia in the irradiated lobe. Tumor control and sur-
vival data were not presented.
Table 3 Local Control Rate (LCR) 12 months after start of radiotherapy for all lesions and lung lesions
All (N = 100) Lung (N = 75)
LCR – 12 months All 93.8% (N = 83) 93.5% (N = 61)
BED ≤ 100 Gy 90.7% (N = 55) p = 0.43 89.7% (N = 39) p = 0.51
BED > 100 Gy 100% (N = 28) 100% (N = 22)
GTV≤ 14 cm3 98.1% (N = 58) p = 0.06 97,9% (N = 51) p = 0.02
GTV > 14 cm3 84.9% (N = 25) 74.1% (N = 10)
Cox regression BED p = 0.36 (0.994) p = 0.21 (0.986)
GTV p = 0.72 (1.013) p = 0.16 (0.986)
p-values indicate significance determined by log-rank test. Cox Regression is shown with p-values and hazard ratio in brackets. (BED: Biologically Effective Dose,
GTV: Gross Tumor Volume).
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Table 4 Clinical studies investigating toxicity and outcome of SBRT with FFF beams
Current study Wang 2014 [31] Prendergast 2013 [29] Alongi 2013 [26] Navarria 2013 [28] Alongi 2012 [27] Scorsetti 2011 [30]
Patients (Lesions) 84 (100) 20 (22) 64 40 46 25 (28) 67 (70)
Tumor Various (mostly lung) HCC Lung Prostate NSCLC Stage I Abdominal/pelvic LN Various (mostly lung)
RT schedule 21 – 66 Gy (3–15 fx) 40 - 75 Gy (3–10 fx) 30 – 60 Gy (3–5 fx) 35 Gy (5 fx) 48 Gy (4 fx) 45 Gy (6 fx) 32 – 75 Gy (3–6 fx)
Median follow-up (range) 11 months (3–46) 7 months (3–13) 12 months (3–25) 11 months (5–16) 16 months (2–24) 6 months (2–19) NA7
Acute toxicity1 ≥G3 0% 5%3,6 2%4 0% 4%4,6 0% 3%4
Late toxicity1 ≥G3 1%2 12%4,5 0% 0% -
Local control 1-y-LC: 94% Actuarial-LC: 95% NA8 NA8 1-y-LC: 100% Actuarial-LC: 100% Actuarial-LC: 89%
1Toxicity was assessed either by number or by lesion; 2Bile duct stricture; 3Radiation induced liver disease (RILD); 4Pulmonary toxicity; 5Brachial plexopathy; 6Data show overall toxicity; 7Minimum follow up 3 months;
8Local control not reported. RT: radiotherapy, fx: fractions, LC: local control, LN: lymph node, y: year, NA: not applicable.
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We report a 1-year local control rate of 94%. All tumors
treated with a PTV surrounding BED > 100 Gy were lo-
cally stable after one year and small lung tumors ≤ 14 cm3
(~3 cm diameter) had a significant lower recurrence rate.
Dependency of tumor control on BED and tumor size is
well known from studies predominantly performed with
flattened beams [19,32,33]. In addition, the toxicity re-
ported by us is similar or even lower in comparison to the
toxicity reported in the literature for SBRT with flattened
beams [17,34-36]. In order to detect small changes in tox-
icity, when FFF beams are used, large randomized studies
would be needed, which are unlikely to be performed, be-
cause FFF beams are rapidly adopted into the clinic and
are FDA-approved. In addition to LCR and toxicity we
also analyzed PFS and OS. Of clinical importance, the PFS
was much lower than the LCR suggesting that patients
tend to recur distant from the irradiated lesion. In addition,
the low numbers of 1-year PFS and OS in primary and
secondary cancers indicate a selection bias of inoperable,
comorbid or extensively pretreated patients.
A limitation of our study is the retrospective design,
which doesn’t allow evaluating all side effects of radio-
therapy in the same manner. On the basis of medical
records we often could not distinguish between toxicity
grade 1 and 2, therefore we focused on side effects of
grade 3 and higher: events that made hospitalization or
prolongation of hospitalization necessary. Because of
only one case of ≥ grade 3 toxicity we could not perform
statistical analysis of toxicity related risk factors (e.g. ra-
diation dose, tumor size, centrally located vs. peripheral
lung tumors, etc.). Although our clinic was the first cen-
ter to implement FFF beams for clinical use, the median
follow-up of 11 months is relatively short with, on the
other hand, the follow-up period ranging up to 41
months.
Conclusion
In our cohort of patients with lung, liver, adrenal gland
and lymph node lesions, who were treated with FFF
beams, the acute and early late toxicity, local control and
survival data are perfectly in range with the literature in-
vestigating SBRT with flattened beams. Therefore the use
of FFF beams for SBRT appears to be safe for these indica-
tions, if carefully applied.
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